The disclosure relates to compounds that act as allosteric inhibitors of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the compounds; and methods of treating or preventing kinase-mediated disorders, including cancer and other proliferation diseases.
披露涉及作为
表皮生长因子受体(
EGFR)变构
抑制剂的化合物;包含这些化合物的药物组合物;以及治疗或预防激酶介导的疾病的方法,包括癌症和其他增殖性疾病。